The presence of progesterone receptor in human breast cancer has been proposed as a mechanism whereby tumor cells respond to estrogen, and its presence may therefore serve as a marker for enhanced hormone responsiveness. Historically, estrogen receptor-positive/progesterone receptor-positive breast carcinoma patients have demonstrated a better response to endocrine therapy than estrogen receptor-positive/ progesterone receptor-negative patients. The use of monoclonal antibodies to determine progesterone receptor status increases the predictive value of immunohistochemical analysis with respect to the response of human tumors to hormonal modulation. This antibody stains human nuclear progesterone receptor in tissue sections by immunohistochemical techniques.
|Tissue Type/Cancer Type||
6 mL – Manual – RTU, 100 Tests – Automation – i6000, 1 mL – Manual – Concentrate, 0.5 mL – Manual – Concentrate, 50 Tests – Automation – Xmatrx, 50 tests – NanoVIP®, 160 Tests – Automation – Xmatrx, 5 slides – Xmatrx, 5 slides – Manual